Akoya Biosciences Reports Second Quarter 2024 Financial and Business Results
Revenue Climbs, Innovation Drives Growth
Marlborough, Mass. -- July 15, 2024 -- GlobeNewswire --
Akoya Biosciences, Inc. (NASDAQ:AKYA), a leading provider of precision medicine solutions, today reported financial and business results for the second quarter and six months ended June 30, 2024.
Key Financial Results:
- Revenue for the second quarter of 2024 was $XX million, a XX% increase compared to the second quarter of 2023.
- Net income for the second quarter of 2024 was $XX million, compared to a net loss of $XX million in the second quarter of 2023.
- Diluted earnings per share for the second quarter of 2024 were $XX, compared to a loss per share of $XX in the second quarter of 2023.
Akoya's strong financial performance was driven by continued demand for its innovative precision medicine solutions, including its multiplex immunofluorescence (mIF) platform and spatial biology solutions.
In the second quarter, Akoya made significant progress in its R&D pipeline, including the launch of its new PhenoCycler-Fusion platform. This innovative platform combines the power of mIF with high-throughput cell cycling analysis, enabling researchers to gain deeper insights into cell biology.
"Our strong financial performance and continued innovation highlight the growing demand for our precision medicine solutions," said Brian McKernan, CEO of Akoya Biosciences. "We are well-positioned to continue our growth trajectory and make a significant contribution to the advancement of precision medicine."
Komentar